Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. However ...

It will reach the market later this month with the task of taking on Pfizer’s first-to-market Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib), which are both approved for RA.

other biologic therapies or Pfizer's JAK inhibitor Xeljanz (tofacitinib). Lilly has its hopes pinned on approval of mirikizumab in UC after it decided to abandon development of the drug in ...

After hours: March 12 at 7:59:30 PM EDT Loading Chart for PFE ...